Departments of 1 Physiology, 2 Biochemistry, and
3 Histology, Marmara University School of Medicine, 81326 Haydarpaa,
stanbul, Turkey; and 4 Department of
Molecular and Cellular Physiology, Louisiana State University,
Shreveport, Louisiana 71130
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The objectives of this study were to characterize the effects of endothelin (ET)-1 on intestinal mucosal parameters and to assess the contribution of polymorphonuclear leukocytes (PMNs), intercellular adhesion molecule-1 (ICAM-1), and a platelet-activating factor (PAF) to the mucosal dysfunction induced by ET-1. Different concentrations of ET-1 (100, 200, and 400 pmol/kg) were infused into the superior mesenteric artery for 10 min, and tissue samples were obtained 30 min after terminating the infusion. ET-1 administration significantly elevated tissue myeloperoxidase activity, plasma carbonyl content, and tissue chemiluminescence intensity, indicating that ET-1 produces PMN infiltration and oxidant stress. Blood-to-lumen clearance of 51Cr-EDTA significantly increased after ET-1 infusion (400 pmol/kg). Monoclonal antibodies against ICAM-1 (1A29, 2 mg/kg), antineutrophil serum, and PAF antagonist (WEB-2086, 10 mg/kg) attenuated the mucosal barrier dysfunction induced by ET-1. Overall, our data indicate that ET-1 causes PMN accumulation, oxidant stress, and mucosal dysfunction in the rat small intestine and that ET-1-induced mucosal dysfunction involves a mechanism that includes a role for PMNs, ICAM-1, and PAF.
oxidant stress; mucosal permeability; intercellular adhesion molecule-1; platelet-activating factor
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
THE REGULATION OF THE MUCOSAL microcirculation is intimately involved in the maintenance of mucosal integrity; hence, the local release of vasoactive mediators from endothelial cells of the microvasculature plays a significant modulatory role. Endothelin (ET)-1, an extremely potent vasoconstrictor peptide with 21 amino acid residues, was originally identified in the culture supernatant of porcine endothelial cells (38). ET-1 is considered to have a physiological role in the control of gastrointestinal blood flow as well as in the modulation of gastrointestinal function (32, 35). In addition, ET-1 has been implicated in the pathogenesis of various microvascular disturbances, including liver ischemia-reperfusion injury (29), hemorrhagic shock-induced gastric mucosal injury (26), and ethanol-induced gastric mucosal damage (25). The involvement of ET-1 in the pathogenesis of various microvascular disturbances was mainly supported by the observations that ET-1 levels increase during these experimental conditions and that ET-1 inhibitors provide a significant level of protection against microvascular disturbances. To evaluate the role of ET-1 in mediating gastrointestinal disease, several investigators have examined the alterations in microvascular permeability induced by ET-1 infusion. Exogenous ET-1 administration produces a marked increase in vascular tone and significant elevation in protein extravasation in the gastric microvasculature, leading to substantial gastric mucosal injury in the rat (1, 9). In another study, direct assessment of the effects of ET-1 on intestinal microcirculation was obtained by using a fluorescence videomicroscopy system (3). It has been shown that reductions in subserosal lymphatic capillary density and mucosal functional capillary density are among the earliest microcirculatory consequences of systemic ET-1 administration at low doses. Higher doses of the peptide produce marked decreases in perfusion parameters in all layers of the small intestine. Moreover, it has been demonstrated that ET-1 induces significant necrotic and hemorrhagic lesions in the small intestine that can be partially inhibited by superoxide dismutase, catalase, a platelet-activating factor (PAF) inhibitor, and a calcium antagonist (nicorandil), indicating that reactive oxygen metabolites (ROM), PAF, and possibly polymorphonuclear leukocytes (PMNs) are involved in the injury process induced by ET-1 (28).
Although there are several possible mechanisms by which ET-1 may contribute to mucosal damage, to date there are no published data that assess the role of ET-1 in the integrity of the intestinal epithelial barrier. It is well established that loss of restrictive mucosal function is closely associated with the severity of intestinal damage and that leaky intestinal mucosa leads to transmural movement of toxic factors into circulation, causing sepsis and possibly multiple organ failure (12). The status of the mucosal barrier can be assessed quantitatively using a 51Cr-labeled EDTA molecule. Administration of 51Cr-EDTA results in an almost instant equilibration across the vasculature (into interstitium) but is greatly restricted by the epithelial layer (4). Hence, the epithelium is the limiting barrier to the movement of 51Cr-EDTA, and increased clearance of this molecule from blood to lumen suggests an impairment in the integrity of the epithelial layer. As a potent vasoconstrictor and an inflammatory agent, it is possible that ET-1 may be an important modulator of events leading to intestinal mucosal barrier dysfunction.
In addition to the vasoactive properties of ET-1, there are several reports in the literature that address the potential role of ET-1 in modulating leukocyte-endothelial cell interactions. It has been shown that ET-1 enhances superoxide generation from human neutrophils stimulated by chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine, whereas neutrophils stimulate endothelial cell production of ET-1 in vitro (17). It has also been shown that ET-1 stimulates neutrophil adhesion to cultured endothelial cells and increases the expression of adhesion molecules on both the neutrophil surface and endothelial cells (13, 23). The participation of ET in an interaction between leukocytes and the endothelium is further supported by in vivo studies demonstrating that ET-1 infusion causes leukocyte rolling and adherence in submucosal venules of the intestinal microcirculation (3). These data raise the possibility that PMNs may be important modulators of the sequel associated with inflammation of the small intestine induced by ET-1. Overall, the objectives of our study were 1) to characterize the effects of ET-1 on intestinal mucosal parameters, including tissue PMN accumulation, oxidant stress, and the permeability of mucosal membranes, and 2) to assess whether altered mucosal barrier function induced by ET-1 is associated with PMNs, intercellular adhesion molecule-1 (ICAM-1), and PAF.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Animals.
Wistar Albino rats of both sexes (250-300 g) were kept in
a room at a constant temperature of 22 ± 2°C with light-dark
cycles of 12:12 h and fed a standard diet and water ad libitum. Studies were approved by the Marmara University Animal Use and Care Committee. Following an overnight (18 h) fast, the rats were anesthetized with
urethan (1.2 g/kg) and a tracheotomy was performed to facilitate breathing. The right carotid artery was cannulated for arterial pressure recording (Nikon Kohden polygraph model AP-621G). The right
jugular vein was also cannulated for the injection of various compounds. A thermometer was inserted into the rectum, and the body
temperature was maintained at 37°C by a heating pad. A midline abdominal incision was made, and small intestine was exteriorized to
facilitate cannulation of the abdominal aorta. A catheter was inserted
from the bifurcation of common iliac arteries into the abdominal aorta
up to the opening of the superior mesenteric artery. ET-1 (Sigma
Chemical, St. Louis, MO) was dissolved in saline, and doses of 100, 200, and 400 pmol/kg were infused at 0.1 ml/min through the
intra-aortic catheter for 10 min. Control animals received the vehicle
(0.1% bovine serum albumin) instead of ET-1. Thirty minutes after the
administration of ET-1 or the vehicle, tissue samples were obtained
from duodenal, jejunal, and ileal segments and stored at 70°C for
subsequent biochemical determinations. Heparinized blood samples were
obtained from the jugular vein at the beginning of the experiment and
from the portal vein at the end of the experiment. The blood was
immediately centrifuged, and plasma was stored at
70°C for the
determination of the protein carbonyls.
Mucosal permeability measurements.
Changes in mucosal permeability were assessed using the blood-to-lumen
clearance of 51Cr-EDTA (obtained from NEN, Boston,
MA). Briefly, after an abdominal incision was made and the abdominal
aorta was cannulated, a jejunal segment (at 15 cm distal to Treitz
ligament) was isolated and cannulated at both ends using Silastic
tubing. The luminal contents were removed by perfusion with warmed
isotonic saline solution (pH 7). Both renal pedicles were ligated to
prevent rapid excretion of the radioisotope marker into urine. After
the surgery was completed, 51Cr-EDTA (100 µCi) in saline
was administered intravenously as a bolus through the jugular vein
followed by a 20-min equilibration period, during which the isolated
intestinal segment was perfused with saline at a rate of 0.5 ml/min but
no clearance measurements were taken. All perfusates were warmed so
that their temperature at the point of entering the intestine was
37°C. After the equilibration period, luminal perfusate was collected
over 10-min periods before and after the administration of various
doses of ET-1 (100, 200, and 400 pmol · kg1 · min
1). Blood
samples (0.3 ml) were taken at the beginning and the end of experiments
from the carotid artery and centrifuged (15,000 rpm) for 5 min. The
amount of radioactivity in the plasma and the perfusate was then
determined by gamma spectroscopy. At the end of the experiment, the
isolated segment of small intestine was removed, rinsed, and weighed.
The plasma-to-lumen clearance of 51Cr-EDTA was calculated
as (4)
![]() |
Endothelin assay.
Portal plasma ET-1 levels were measured in control and in
intra-arterial ET-1-treated groups at a dose of 400 pmol · kg1 · min
1. Blood
samples were drawn from the portal vein at the end of each experiment
and were collected in chilled polypropylene tubes containing 1 mg/ml
EDTA and 500 KIU/ml aprotinin (Trasylol; Bayer). The blood samples were
centrifuged at 4°C, and the plasma samples were collected and stored
at
80°C until assay. Plasma levels of ET-1 were measured with a
sandwich immunoassay technique (BBE-5; R&D Systems). According to the
manufacturer, intra-assay coefficient of variation is <4.6% and
interassay coefficient of variation is <6.5%. Sensitivity of the kit
is 0.25 pg/ml. The cross-reactivity of the kit with big ET-1 was <1%
and with ET-3 was <14%.
Tissue myeloperoxidase measurements. Tissue associated myeloperoxidase (MPO) activity was determined in 0.2- to 0.5-g samples. The tissue samples were homogenized in 10 vol of ice-cold potassium phosphate buffer (20 mM K2HPO4, pH 7.4). The homogenate was centrifuged at 12,000 rpm for 10 min at 4°C, and the supernatant was discarded. The pellet was then rehomogenized with an equivalent volume of 50 mM K2HPO4 containing 0.5% (wt/vol) hexadecyltrimethylammonium hydroxide. MPO activity was assessed by measuring the H2O2-dependent oxidation of o-dianisidine · 2HCl. One unit of enzyme activity is defined as the amount of the MPO present that causes a change in absorbance of 1.0/min at 460 nm and 37°C (2).
Assessment of oxidant stress. Protein oxidation was quantified using the interaction between 2,4-dinitrophenylhydrazine (DNP; Sigma) and the carbonyls generated from the oxidative modification of proteins to yield a chromophore that absorbs strongly at 380 nm. Briefly, protein in the aliquots (0.5 ml) was precipitated by the addition of 20% TCA. Precipitated protein was collected by centrifugation and resuspended in 0.5 ml of 10 mM DNP in 2 M HCl. The samples were incubated for 1 h at 25°C with occasional mixing. Protein was then precipitated by the addition of 20% TCA and collected by centrifugation, and the pellet was washed three times with 1 ml of an ethanol-ethyl acetate (1:1) solution to remove any unreacted DNP. The protein precipitant was solubilized by the addition of 1 ml of 1 N NaOH, and the absorbance was determined at 380 nm. The carbonyl content was calculated assuming a molar extinction coefficient of 22,000 (21).
Chemiluminescence measurements were done using a liquid scintillation counter (Tricarb 1500; Packard Instruments) in out-of-coincidence mode with a single active photomultiplier tube. Fresh intestinal samples were gently transferred to precounted glass scintillation vials containing phosphate buffered saline at pH 7.4 supplemented with HEPES (0.02 mol/l). Luminescence was recorded at room temperature after the addition of 0.2 mM lucigenin (bis-N-methylacridinium nitrate; Sigma) or 0.2 mM luminol (5-amino-2,3-dihydro-1,4-phthalazinedione; Sigma). Counts were obtained at 1-min intervals over a period of 60 min, and each point was calculated as counts per minute per milligram of tissue after substraction of scintillation vial background. The results were expressed as area under the curve, with the integration of the area by the trapezoidal rule (36).Tissue analysis. Samples from the standardized regions of the duodenum, jejunum, and ileum were fixed with neutral buffered formalin and processed by routine techniques before embedding in paraffin wax. Sections (4 mm) were stained with hematoxylin and eosin and examined under a light microscope. For histological assessment of intestinal injury, a 0-3 grading scale was used as follows: 0 = having normal histology; 1 = subepithelial vasocongestion and epithelial cell loss, injury at villus tips; 2 = mucosal congestion, hemorrhage, and focal necrosis, with loss of more than half of villi; and 3 = having damage extending to submucosa or transmucosa. All assessments of damage were performed by an observer unaware of the treatment.
Statistics. All values are reported as means ± SE. Student's t-test and one-way analysis of variance with the Newman-Keuls post hoc test were used to determine whether data from different groups were statistically different. P < 0.05 was considered statistically significant.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Close intra-arterial administration of ET-1 at various doses did
not cause any significant change in mean arterial pressure. The mean
arterial pressures before and after ET-1 infusion (400 pmol · kg1 · min
1) were
90.34 ± 3.45 mmHg and 95.84 ± 4.92 mmHg, respectively, which slowly declined to 83.13 ± 7.8 mmHg 30 min later. In
permeability experiments, the mean arterial pressure significantly
decreased at 60 min following 400 pmol · kg
1 · min
1 ET-1
administration. Treatment with ANS, ICAM-1 MAb, or PAF receptor antagonist WEB-2086 did not change the arterial pressure values compared with the ET-1 group alone.
The basal ET-1 concentration in the portal plasma was 6.37 ± 3.05 pg/ml. In the ET-1-treated group, intra-arterial infusion of ET-1 at a
dose of 400 pmol · kg1 · min
1 resulted
in an ~25-fold increase (162.25 ± 16.72 pg/ml) in portal blood
ET-1 levels at 30 min after its administration.
Figure 1 illustrates the changes in MPO
values induced by administration of different doses of ET-1. In the
control group, MPO activities were 139.33 ± 14.9, 133.91 ± 12.75, and 129.39 ± 18.1 U/g in the duodenal, jejunal, and ileal
segments, respectively. Basal MPO activities in the duodenum, jejunum,
and ileum were found to be not statistically different. Intra-arterial
administration of ET-1 at various doses increased the magnitude of the
PMN infiltration in all segments of small intestine in a dose-dependent
fashion, with the 400 pmol · kg1 · min
1 dose
exhibiting the greatest response. All intestinal segments responded to
400 pmol/kg ET-1 with a significant increase in MPO activity.
|
Table 1 summarizes the changes in plasma
carbonyl content and the tissue chemiluminescence intensity in response
to administration of various doses of ET-1. In plasma samples,
formation of carbonyl groups, which is an indicator of protein
oxidation, significantly increased after ET-1 infusion at a dose of 400 pmol · kg1 · min
1.
Luminol- and lucigenin-enhanced tissue chemiluminescence intensities were significantly increased in animals treated with 400 pmol · kg
1 · min
1 of ET-1
compared with control values, indicating the enhanced ROM production in
the intestinal samples.
|
Figure 2 illustrates the time-dependent
effects of ET-1 infusions (100, 200, and 400 pmol · kg1 · min
1) on
intestinal blood-to-lumen clearance of 51Cr-EDTA. In
control animals, basal 51Cr-EDTA clearance did not
significantly change throughout the 1-h measurement period. ET-1
increased the mucosal permeability in a dose-dependent fashion, in
which significant elevations in mucosal permeability were observed at a
dose of 400 pmol · kg
1 · min
1.
Clearance values significantly increased during the infusion period,
leveled at ~2.5 times the preperfusion values for the next 20 min,
and then reached the peak permeability values (~6.6-fold) at the end
of the experiment.
|
Figure 3 compares the tissue MPO
responses to ET-1 administration (400 pmol · kg1 · min
1) in
untreated animals and in animals treated with ET-1 plus ICAM-1-specific MAb 1A29, ANS, or PAF receptor antagonist WEB-2086. Tissue samples were
obtained from the perfused jejunal segments at the end of permeability
measurements. Tissue-associated MPO activity significantly increased in
animals treated with ET-1. Pretreatment with MAb 1A29 and ANS
significantly reduced PMN infiltration elicited by ET-1
administration, indicating that both approaches to inhibition of
PMN accumulation were effective. The effectiveness of ANS in reducing
the number of PMNs was also confirmed in the peripheral blood samples.
Neutrophil counts before and after the injections of ANS were 3.68 ± 1.1 × 106 and 0.95 ± 0.53 × 106 cells/ml blood, respectively (P < 0.01 compared with pretreatment values; data not shown). On the other hand,
PAF receptor antagonist did not significantly alter the elevated MPO
activities normally observed after ET-1 administration.
|
Figure 4 shows the time-dependent changes
in mucosal permeability values assessed in ET-1-treated (400 pmol/kg)
and ET-1 plus MAb 1A29-, ANS-, or WEB-2086-treated rats. MAb 1A29
pretreatment lowered the clearance values compared with the
ET-1-treated group alone. This decrease in permeability was especially
evident during the first 30 min of the experiment, reaching statistical
significance at 0, 10, and 20 min after ET-1 administration. Similarly,
pretreatment of animals with ANS reduced the ET-1-induced increase in
mucosal permeability in which significant decreases were observed at 0 and 20 min after ET-1 infusion. Administration of PAF receptor antagonist WEB-2086 reduced the elevated clearance values during the
entire measurement period; however, significant decreases were observed
between 30 and 60 min of measurement.
|
Figure 5 shows light micrographs of the
small intestine from rats infused with ET-1 (400 pmol · kg1 · min
1) or ET-1
plus ANS, WEB-2086, or MAb 1A29. In the ET-1-administered group, severe
lesions were most commonly observed and consisted of disruption of more
than half of the villi, with diffuse microvascular congestion and
hemorrhagic damage (Fig. 5A). With the use of ANS, WEB-2086,
or MAb 1A29, severe mucosal destruction induced by ET-1 was partially
prevented, and instead of these lesions, lifting of epithelial cell
layer, injury at villus tips, mucosal lymphangiectasia, and submucosal
edema were commonly observed (Fig. 4, B-D). The degree
of mucosal damage expressed by the histological index was significantly
lowered by the pretreatment with ANS, WEB-2086, or MAb 1A29 for each
compared with those receiving ET-1 alone (Table
2).
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Local intra-arterial administration of ET-1 induces extensive hemorrhagic damage in the rat gastrointestinal tract that is morphologically similar to human ischemic bowel necrosis (28). The effect of ET-1 has been attributed to the potent vasoactive properties of this peptide. In addition, increased vascular permeability in the gastrointestinal organs has been reported in response to ET-1 administration (9). Recently, a number of studies have shown that ET-1 is a neutrophil-activating agent causing the accumulation of neutrophils to various vascular beds, including lung, kidneys, and heart (8, 15, 23). However, there has not been a systematic analysis of the mucosal alterations that are produced by ET-1. In the present study, we have employed a rat model of ET-1-induced intestinal injury to assess the effects of ET-1 on intestinal mucosal parameters. The results of our study suggest that infusion of ET-1 into the superior mesenteric artery causes a dose-dependent increase in PMN accumulation, elevates mucosal permeability to 51Cr-EDTA molecules, and produces marked changes in the formation of ROMs.
In an attempt to determine whether ROMs contribute to the pathogenesis
of ET-1-induced mucosal injury, we determined the plasma levels of
carbonyls and the tissue chemiluminescence intensity. The reactions of
endogenous proteins with ROMs lead to the oxidation of some amino acid
side chains to carbonyl derivatives (33). In the present
study, ET-1 administration at a dose of 400 pmol · kg1 · min
1
significantly increased carbonyl formation, indicating an oxidative modification of plasma proteins. These observations are consistent with
the previously published report demonstrating that pretreatment with
superoxide dismutase/catalase attenuates ET-1-induced bowel damage
(28). Although there is circumstantial evidence that supports the role of ROMs, the enhanced O2
·
production after ET-1 administration has not been demonstrated. Luminol- and lucigenin-dependent chemiluminescence is a very sensitive means of detecting ROM levels in biological media (34).
Luminol-enhanced chemiluminescence has often been used to study the
MPO-dependent oxidative process and the generation of hydrogen peroxide
and hypochlorous acid in particular (5). On the other
hand, lucigenin responds more specifically to superoxide than luminol
(6). Using both techniques, we showed that ET-1 increases
the photoemission observed with chemiluminescence in the rat small
intestine, suggesting increased ROM production after ET-1
administration. The source of ROMs in this model of intestinal injury
may include the activation of parenchymal cell-associated xanthine
oxidase and/or activation of granulocyte-associated NADPH oxidase from
granulocytes that normally reside in the intestinal mucosa. The
association of xanthine oxidase-derived free radicals with
ischemia-reperfusion injury has been well documented in many studies
(11). Miura et al. (28) have recently shown
that local infusion of ET-1 at 1 nmol/kg significantly decreases
intestinal blood flow to 15% of control without changing systemic
arterial pressure. It is conceivable that local microcirculatory
disturbances induced by ET-1 could cause the activation of xanthine
oxidase, an event that increases ROM production.
In addition to vasoactive properties, several ET-1-related mechanisms
have been described as PMN properties, including Ca2+
mobilization (24), O2· production
(17), adhesion to endothelial cells, and aggregation (10). Investigators have shown that increased ET-1
formation and PMN accumulation are coexisting phenomena in pathological circumstances such as ischemia-reperfusion injury (8)
and endotoxin-induced microcirculatory disturbance (27).
In the present study, by measuring the tissue-associated MPO
activities, PMN infiltration was monitored in duodenal, jejunal, and
ileal samples. We have demonstrated that intra-arterial administration
of ET-1 at a dose of 400 pmol · kg
1 · min
1
significantly increases the number of PMNs in all regions of small
intestine, indicating a possible role of PMNs in ET-1-induced intestinal damage. Our results also indicate that the magnitude of PMN
infiltration does not differ significantly between the regions of the
small intestine exposed to the same doses of ET-1. The mechanisms by
which ET-1 increases PMN accumulation in the small intestine remain
unclear, but several possibilities have been proposed, including a
direct activating effect of ET-1 on PMNs. ET-1 induces neutrophil
adhesion to plastic surfaces, suggesting a predominant effect of ET-1
on the neutrophil site of the adhesion. It has been also shown that
ET-1 stimulates neutrophil adhesion to cultured endothelial cells by an
effect on the expression of CD18 and CD11b on the neutrophil surface
and ICAM-1 on the endothelial cells (13, 23).
Recent work by Boros et al. (3) provides direct in vivo
evidence of ET-1-mediated leukocyte-endothelial cell interactions by
demonstrating that ET-1 induces leukocyte rolling and adherence through
a predominantly ETA receptor-mediated mechanism in the
submucosal venules of the intestinal microcirculation. The authors
proposed that microvascular flow-related alterations (low shear stress)
and secondary mediators released during microvascular impairment may
stimulate leukocyte-endothelial cell interactions. In that study,
however, the dose of ET-1 that was used to induce leukocyte adhesion
did not significantly increase microvascular permeability. Furthermore,
it remains unclear whether ET-1-induced leukocyte adhesion eventually
triggers the destructive properties of PMNs, leading to tissue injury.
Lopez-Belmonte and Whittle (22) recently demonstrated that
the ET-1-induced increase in gastric vascular albumin leakage is
unaffected by pretreatment with antineutrophil serum, indicating that
neutrophils are not involved in the gastric vascular dysfunction
induced by ET-1. Although ET-1 is implicated as an important modulating
agent for PMN functions, it is not entirely clear whether or not PMNs
are a prerequisite for ET-induced tissue injury. The observation that ET-1 infusion significantly increases the mucosal permeability to a
51Cr-EDTA molecule at a dose of 400 pmol · kg
1 · min
1 indicates
that ET-1 may be an important modulator of events leading to intestinal
mucosal barrier dysfunction. It is conceivable that permeability
changes induced by ET-1 may be associated with activated tissue PMNs.
To assess this possibility, we compared the mucosal permeability
elicited by ET-1 in ANS-pretreated animals with those which received
ET-1 infusion alone. ANS significantly reduced the ET-1-induced
increases in both tissue MPO activity and mucosal permeability values,
and significant differences in mucosal permeability were observed
during the early measurement periods. The results of this analysis
suggest that tissue PMNs are the important mediators of ET-1-induced
mucosal dysfunction. Another approach to investigating the role of PMNs
in ET-1-induced permeability changes involved the pretreatment of
animals with the ICAM-1-specific MAb 1A29 before ET-1 infusion.
ET-1-induced ICAM-1 expression has been previously demonstrated by
investigators who showed that ET-1 increases ICAM-1 expression on the
surface of brain microvascular cells and on the aortic endothelial
cells (13). The administration of MAb 1A29 significantly
lowered the clearance values during the first 30 min of our experiments
compared with the ET-1 group alone. The antiadhesive effect of MAb 1A29
has been confirmed by tissue MPO measurements, which were found to be
significantly less than untreated values. Furthermore, the degree of
mucosal damage expressed by the histological index was found to be
significantly lower in both ANS- and MAb 1A29-treated animals than in
untreated animals, indicating that PMNs play an important role in the
induction of injury by ET-1. However, the observation that pretreatment with ANS and MAb 1A29 partially reduces the alterations in mucosal barrier function indicates that PMN-independent mechanisms must also be considered.
The lack of a significant effect of lower doses of ET-1 on mucosal
permeability as well as tissue PMN accumulation and oxidant stress
indicates that 400 pmol · kg1 · min
1 is a dose
that produces marked inflammatory changes in the intestinal mucosa. In
our experiments, 400 pmol · kg
1 · min
1
intra-arterial infusion of ET-1 resulted in an ~25-fold increase in
portal blood ET-1 levels at 30 min after its administration. It is
generally accepted that ET-1 is mainly released from the endothelial
cell abluminally (30), and serum concentrations may be
poor indicators of actual local tissue concentrations in pathophysiological conditions. However, a prolonged, ~15- to 30-fold increase in plasma ET levels has also been reported after
endotoxin-induced microcirculatory disturbances in the rat small
intestine and liver (7, 27), which were
comparable to increased levels of ET-1 in the present study.
To investigate the role of PAF in ET-1-induced alterations in mucosal permeability, we pretreated the rats with PAF receptor antagonist WEB-2086 before ET-1 infusion. Our results indicate that administration of WEB-2086 significantly lowers the ET-1-induced changes in clearance values without altering the ET-1-induced increase in tissue MPO measurements. These results are consistent with the previous observations indicating that PAF antagonists inhibit ET-1-induced intestinal damage (28) and gastric vascular leakage of albumin, an effect that is suggested to be neutrophil independent (22). Recent work from Miura et al. (27) indicates that increased PAF production in endotoxin-induced microcirculatory disturbance is closely associated with increased ET-1 levels through the ETA receptor in rat small intestine. Because ETA receptor antagonist BQ-123 is effective in attenuating the endotoxin-induced production of PAF, the authors suggest that ET-1 may directly induce PAF production and/or that PAF production is increased as a consequence of mucosal damage induced by ET-1. Although PAF is known as a potent mediator of the PMN accumulation, considering the effect of WEB-2086 on time course changes in mucosal permeability (especially evident during the second half of the experiment) and its inefficacy on elevated tissue MPO activity normally observed after ET-1 administration, it is conceivable that there may be other factors that are responsible for ET-1-induced PMN accumulation in the small intestine. Moreover, it is also possible that PMN-independent systems are activated (e.g., protease release) as the injury process continues and that tissue factors are released such as PAF or cytokines, which may directly or indirectly cause the release of toxic metabolites (14, 16, 19). Finally, it is likely that an agent that activates Ca2+ influx into cells also exerts a major effect on other inflammatory cells, including mast cells and platelets, all of which can release substances that may cause microvascular dysfunction (20). Recent work from Shigematsu et al. (31) indicates that ET-1 plays an important role in mast cell-mediated responses via ETA receptors in intestinal anaphylaxis. Yamamura et al. (37) have demonstrated that cultured mouse bone marrow-derived mast cells are capable of releasing histamine and leukotriene C4 in response to ET-1 stimulation via ETA receptors. They also found that ET-1 is one of the most potent histamine-releasing factors in mouse peritoneal mast cells discovered to date. Additional studies are required to test the validity of these mechanisms on ET-1-induced intestinal mucosal dysfunction.
In summary, we have demonstrated that neutrophil depletion and blockage of ICAM-1 attenuates the increased mucosal permeability and microscopic damage observed in the rat small intestine following ET-1 administration. This indicates that neutrophils play an important role in mediating the mucosal dysfunction elicited by ET-1. Moreover, our results also demonstrate that ROM production and mucosal barrier dysfunction are important properties of ET-1-induced intestinal inflammation. Finally, increased mucosal permeability observed in the rat small intestine following ET-1 administration involves a mechanism that includes a role for PAF.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Dr. Julian Panes (Dept. of Gastroenterology, Hospital Clinic, University of Barcelona, Spain) for the generous gift of ICAM-1 monoclonal antibody (MAb 1A29).
![]() |
FOOTNOTES |
---|
Preliminary data from this study were presented at Digestive Diseases Week and the 98th Annual Meeting of the American Gastroenterological Association, 1997, Washington, DC and Digestive Diseases Week and the 99th Annual Meeting of the American Gastroenterological Association, May 16-22, 1998, New Orleans, LA.
This work was supported by National Institutes of Health Grants TW-00755 and HL-26441.
Address for reprint requests and other correspondence: H. Kurtel, Dept. of Physiology, Marmara Univ., School of Medicine 81326 Haydarpaa,
stanbul, Turkey (E-mail:
hkurtel{at}superonline.com).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Received 1 December 1998; accepted in final form 23 March 2000.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Belmote, JL,
Whittle BJR,
and
Moncada S.
The actions of nitric oxide donors in the prevention or induction of injury to the rat gastric mucosa.
Br J Pharmacol
108:
73-78,
1993[ISI][Medline].
2.
Bradley, PP,
Priebat DA,
Christersen RD,
and
Rothstein G.
Measurement of cutaneous inflammation. Estimation of neutrophil content with an enzyme marker.
J Invest Dermatol
78:
206-209,
1982[Abstract].
3.
Boros, M,
Massberg S,
Baranyi L,
Okada H,
and
Messmer K.
Endothelin-1 induces leukocyte adhesion in submucosal venules of the rat small intestine.
Gastroenterology
114:
103-114,
1998[ISI][Medline].
4.
Crissinger, KD,
Kvietys PR,
and
Granger DN.
Pathophysiology of gastrointestinal mucosal permeability.
J Intern Med
228, Suppl 1:
145-154,
1990[ISI].
5.
Dahlgren, C,
and
Stendahl O.
Role of myeloperoxidase in luminol-dependent chemiluminescence of polymorphonuclear leukocytes.
Infect Immun
39:
736-741,
1983[ISI][Medline].
6.
Davies, GR,
Simmond NJ,
Stevens TRJ,
Sheaf MT,
Bnavala N,
Lauransen IF,
Blake DR,
and
Rampton DS.
Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo.
Gut
35:
179-185,
1994[Abstract].
7.
Eakes, AT,
Howard KM,
Miller JE,
and
Olson MS.
Endothelin-1 production by hepatic endothelial cells: characterization and augmentation by endotoxin exposure.
Am J Physiol Gastrointest Liver Physiol
272:
G605-G611,
1997
8.
Espinosa, G,
Farre AL,
Cernadas MR,
Manzarbeitia F,
Tan D,
Digiuni E,
Mosquera JR,
Monton M,
Millas I,
Hernando L,
Casado S,
and
Caramelo C.
Role of endothelin in the pathophysiology of renal ischemia-reperfusion in normal rabbits.
Kidney Int
50:
776-782,
1996[ISI][Medline].
9.
Filep, JG,
Filep EF,
Rousseau A,
Siriois P,
and
Fournier A.
Vascular responses to endothelin-1 following inhibition of nitric oxide synthesis in the conscious rat.
Br J Pharmacol
110:
1213-1221,
1993[Abstract].
10.
Gomez Garre, D,
Guerra M,
Gonzalez E,
Lopez Farre A,
Riesco A,
Caramelo C,
Escanero F,
and
Egido J.
Aggregation of human polymorphonuclear leukocytes by endothelin: role of platelet activating factor.
Eur J Pharmacol
224:
167-172,
1992[ISI][Medline].
11.
Grisham, MB,
Hernandez LA,
and
Granger DN.
Xanthine oxidase and neutrophil infiltration in intestinal ischemia.
Am J Physiol Gastrointest Liver Physiol
251:
G267-G574,
1986.
12.
Haglund, U,
Bulkley GB,
and
Granger DN.
On the pathophysiology of intestinal ischemic injury. Clinical review.
Acta Chir Scand
153:
321-324,
1987[ISI][Medline].
13.
Hayasaki, Y,
Nakajima M,
Kitano Y,
Iwasaki T,
Shimamura T,
and
Iwaki K.
ICAM-1 expression on cardiac myocytes and aortic endothelial cells via their specific endothelin receptor subtype.
Biochem Biophys Res Commun
229:
817-824,
1996[ISI][Medline].
14.
Helset, E,
Kjaeve J,
and
Hauge A.
Endothelin-1-induced increases in microvascular permeability in isolated perfused rat lungs requires leukocytes and plasma.
Circ Shock
39:
15-20,
1993[ISI][Medline].
15.
Helset, E,
Lindal S,
Olsen R,
Myklebust R,
and
Jørgensen L.
Endothelin-1 causes sequential trapping of platelets and neutrophils in pulmonary microcirculation in rats.
Am J Physiol Lung Cell Mol Physiol
271:
L538-L546,
1996
16.
Helset, E,
Sildnes T,
and
Konopski ZS.
Endothelin-1 stimulates monocytes in vitro to release chemotactic identified as interleukin-8 and monocyte chemotactic protein-1.
Med Inf (Lond)
3:
155-160,
1994.
17.
Ishida, K,
Takeshige K,
and
Minakami S.
Endothelin-1 enhances superoxide generation of human neutrophils stimulated by the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine.
Biochem Biophys Res Commun
173:
496-500,
1990[ISI][Medline].
18.
Kurose, I,
Kubes P,
Wolf R,
Anderson DC,
Paulson J,
Miyasaka M,
and
Granger DN.
Inhibition of nitric oxide production: mechanisms of vascular albumin leakage.
Circ Res
73:
164-171,
1993[Abstract].
19.
Kurose, I,
Miura S,
Fukumura D,
Ttashiro H,
Imaeda H,
Shiozaki H,
Suematsu M,
Nagata H,
Sekizuka E,
and
Tsuchiya M.
Role of platelet activating factor on the fibrinolytic activation in the pathogenesis of gastric mucosal damage induced by endothelin-1.
Gut
33:
868-871,
1992[Abstract].
20.
Kurose, I,
Wolf R,
Grisham MB,
and
Granger DN.
Modulation of ischemia/reperfusion-induced microvascular dysfunction by nitric oxide.
Circ Res
74:
376-382,
1994[Abstract].
21.
Levine, RL,
Garland D,
Oliver CN,
Amici A,
Climent I,
Lenz A,
Ahn B,
Shaltiel S,
and
Stadtman ER.
Determination of carbonyl content in oxidatively modified proteins.
Methods Enzymol
186:
464-478,
1990[Medline].
22.
Lopez-Belmonte, J,
and
Whittle BJR
Endothelin-1 induces neutrophil-independent vascular injury in the rat gastric microcirculation.
Eur J Pharmacol
278:
R7-R9,
1995[ISI][Medline].
23.
Lopez Farre, A,
Riesco A,
Espinosa G,
Digiuni E,
Cernadas MR,
Alvarez V,
Monton M,
Rivas F,
Gallego MJ,
Egido J,
Casado S,
and
Caramelo C.
Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart.
Circulation
88:
1166-1171,
1993[Abstract].
24.
Lopez Farre, A,
Riesco A,
Moliz M,
Egido J,
Casado S,
Hernando L,
and
Caramelo C.
Inhibition by L-arginine of endothelin-mediated increase in cytosolic calcium in human neutrophils.
Biochem Biophys Res Commun
178:
884-891,
1991[ISI][Medline].
25.
Masuda, E,
Kawano S,
Nagano K,
Tsuji S,
Takei Y,
Hayashi N,
Tsujii M,
Oshita M,
Michida T,
Kobayashi I,
Peng H,
Fusamoto H,
and
Kamada T.
Role of endogenous endothelin in pathogenesis of ethanol-induced gastric mucosal injury in rats.
Am J Physiol Gastrointest Liver Physiol
265:
G474-G481,
1993
26.
Michida, T,
Kawano S,
Masuda E,
Kobayashi I,
Nishimura Y,
Tsujii M,
Hayashi N,
Takei Y,
Tsuji S,
Nagano K,
Fusamoto H,
and
Kamada T.
Role of endothelin 1 in hemorrhagic shock-induced gastric mucosal injury in rats.
Gastroenterology
106:
988-993,
1994[ISI][Medline].
27.
Miura, S,
Fukumura D,
Kurose I,
Higuchi H,
Kimura H,
Tsuzuki Y,
Shigematsu T,
Han J-Y,
Tsuchiya M,
and
Ishii H.
Roles of ET-1 in endotoxin-induced microcirculatory disturbance in rat small intestine.
Am J Physiol Gastrointest Liver Physiol
271:
G461-G469,
1996
28.
Miura, S,
Kurose I,
Fukumura D,
Suematsu M,
Sekizuka E,
Tashiro H,
Serizawa H,
Asako H,
and
Tsuchiya M.
Ischemic bowel necrosis induced by endothelin-1: an experimental model in rats.
Digestion
48:
163-172,
1991[ISI][Medline].
29.
Moritaka, G,
Takei Y,
Kawano S,
Nagano K,
Tsuji S,
Masuda E,
Nishimura Y,
Okumura S,
Kashiwagi T,
Fusamoto H,
and
Kamada T.
Endothelin-1 is involved in the pathogenesis of ischemia-reperfusion liver injury by hepatic microcirculatory disturbances.
Hepatology
19:
675-681,
1994[ISI][Medline].
30.
Rubanyi, GM,
Keith TL,
and
Highsmith RF.
Endothelin receptors and calcium signaling.
FASEB J
9:
1196-1204,
1995
31.
Shigematsu, T,
Miura S,
Hirokawa M,
Hokari R,
Higuchi H,
Tsuzuki Y,
Kimura H,
Nakatsumi RC,
Serizawa H,
Saito H,
and
Hiromasa I.
Endothelins promote egg albumin-induced intestinal anaphylaxis in rats.
Gastroenterology
115:
348-356,
1998[ISI][Medline].
32.
Spokes, R,
Ghatei M,
and
Bloom S.
Studies with endothelin-3 and endothelin-1 on rat blood pressure and isolated tissues: evidence of multiple receptor subtypes.
J Cardiovasc Pharmacol
13, Suppl 5:
S191-S192,
1989[ISI][Medline].
33.
Stadtman, ER,
and
Berlett BS.
Reactive oxygen-mediated protein oxidation in aging and disease.
Chem Res Toxicol
10:
485-494,
1997[ISI][Medline].
34.
Stevens, P.
Lucigenin and luminol-dependent chemiluminescence to selectively differentiate the oxidative pathways of phagocytic cells in cellular chemiluminescence.
In: Cellular Chemiluminescence, edited by Van Dyke K,
and Castranova V.. Boca Raton, FL: CRC, 1987, p. 105-112.
35.
Takahashi, K,
Jones P,
Kans S,
Lam H,
Spokes R,
Ghatei M,
and
Bloom S.
Endothelin in the gastrointestinal tract.
Gastroenterology
99:
1660-1667,
1990[ISI][Medline].
36.
Van Dyke, K.
Helpful hints for cellular chemiluminescence assay.
In: Cellular Chemiluminescence, edited by Van Dyke K,
and Castranova V.. Boca Raton, FL: CRC, 1987, p. 44-45.
37.
Yamamura, H,
Nabe T,
Kohno S,
and
Ohata K.
Endothelin-1 induces release of histamine and leukotriene C4 from mouse bone marrow-derived mast cells.
Eur J Pharmacol
257:
235-242,
1994[ISI][Medline].
38.
Yanagisawa, M,
Kurihara H,
Kimura S,
Tomobe Y,
Kobayashi M,
Mitsui Y,
Yazaki Y,
Goto K,
and
Masaki T.
A novel potent vasoconstrictor peptide produced by vascular endothelial cells.
Nature
332:
411-415,
1988[ISI][Medline].